Last €8.56 EUR
Change Today 0.00 / 0.00%
Volume 0.0
XYXR On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:16 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

raptor pharmaceutical corp (XYXR) Snapshot

Open
€8.34
Previous Close
€8.56
Day High
€8.56
Day Low
€8.34
52 Week High
02/20/14 - €13.87
52 Week Low
04/28/14 - €5.33
Market Cap
536.8M
Average Volume 10 Days
381.4
EPS TTM
--
Shares Outstanding
62.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RAPTOR PHARMACEUTICAL CORP (XYXR)

raptor pharmaceutical corp (XYXR) Related Bloomberg News

View More Bloomberg News

raptor pharmaceutical corp (XYXR) Related Businessweek News

No Related Businessweek News Found

raptor pharmaceutical corp (XYXR) Details

Raptor Pharmaceuticals Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. It markets PROCYSBI, a delayed-release capsule used for the management of nephropathic cystinosis in adults and children six years and older in the United States. The company also commercializes PROCYSBI in the 28 member states of the European Commission plus Norway, Liechtenstein, and Iceland. Its clinical development products include RP103 used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company’s other clinical-stage product candidate is Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical programs comprise cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

70 Employees
Last Reported Date: 03/17/14
Founded in 2005

raptor pharmaceutical corp (XYXR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Director...
Total Annual Compensation: $410.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $350.0K
Chief Business Officer
Total Annual Compensation: $292.0K
Chief Medical Officer and Chief Medical Offic...
Total Annual Compensation: $112.8K
Compensation as of Fiscal Year 2013.

raptor pharmaceutical corp (XYXR) Key Developments

Raptor Pharmaceutical Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year 2014

Raptor Pharmaceutical Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's net product sales were $16,313,000 against $21,000 a year ago. Loss from operations was $9,085,000 against $15,998,000 a year ago. Net loss before provision for income taxes was $12,687,000 or $0.20 basic and diluted per share against $24,121,000 or $0.43 basic and diluted per share a year ago. Non-GAAP loss was $9,418,000 or $0.15 basic and diluted per share against $22,275,000 or $0.40 basic and diluted per share a year ago. For the six months, the company's net product sales were $28,447,000 against $21,000 a year ago. Loss from operations was $19,876,000 against $32,273,000 a year ago. Net loss before provision for income taxes was $27,572,000 or $0.44 basic and diluted per share against $40,048,000 or $0.73 basic and diluted per share a year ago. Non-GAAP loss was $21,934,000 or $0.35 basic and diluted per share against $36,451,000 or $0.66 basic and diluted per share a year ago. The company is increasing net product sales guidance for PROCYSBI to a range of $65 million to $70 million for 2014 compared to previous guidance of $55 million to $65 million. On a non-GAAP basis, excluding non-cash stock-based compensation expense, operating expenses consisting of SG&A and R&D are expected to be in the range of $80 million to $90 million in 2014. GAAP operating expenses for 2014 are not readily determinable due to the volatility of the company's common stock, which directly affects stock-based compensation expense. The company's cash and cash equivalents, after the recent financing in July, are expected to be sufficient to fund operations through at least the first half of 2016, based on current operating plan assumptions.

Raptor Pharmaceuticals Corp. Receives Orphan Drug Designation for Cysteamine Bitartrate in Huntington's Disease from the European Commission

Raptor Pharmaceuticals Corp. announced that the European Commission (EC) approved its application for orphan drug designation of cysteamine bitartrate, the active ingredient in RP103, for the treatment of Huntington's disease. The decision follows a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) in June. In February of this year, Raptor announced encouraging top line results from a planned 18-month analysis of the blinded, randomized, placebo-controlled phase of its ongoing CYST-HD clinical trial of RP103, its proprietary delayed release cysteamine bitartrate capsule, in patients with early-stage Huntington's disease. RP103 was designated an Orphan Medicinal Product for the treatment of Huntington's disease because it meets the conditions established by the EC under council Regulation 141/2000. Orphan Drug Exclusivity is designed to provide regulatory and financial incentives for companies to develop and market therapies that treat life-threatening or debilitating conditions with a prevalence in the EU of not more than five in 10,000. Huntington's disease prevalence meets the criteria as defined by this regulation. The COMP also considers whether there is any satisfactory method of prevention, diagnosis or treatment or if the medicinal product being considered will be of significant benefit to those affected by the condition. Raptor submitted the 18-month CYST-HD results as part of the orphan application.

Raptor Pharmaceutical Corp. Announces Resignation of Executives

Raptor Pharmaceutical Corp. announced that effective July 28, 2014, each of Vijay B. Samant and Timothy P. Walbert resigned from the Board of Directors of Raptor Pharmaceutical Corp.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XYXR:GR €8.56 EUR 0.00

XYXR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XYXR.
View Industry Companies
 

Industry Analysis

XYXR

Industry Average

Valuation XYXR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RAPTOR PHARMACEUTICAL CORP, please visit www.raptorpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.